Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines
The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 1999-09, Vol.42 (18), p.3711-3717 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3717 |
---|---|
container_issue | 18 |
container_start_page | 3711 |
container_title | Journal of medicinal chemistry |
container_volume | 42 |
creator | Ding, Charles Z Rovnyak, George C Misra, Raj N Grover, Gary J Miller, Arthur V Ahmed, Syed Z Kelly, Yolanda Normandin, Diane E Sleph, Paul G Atwal, Karnail S |
description | The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide. |
doi_str_mv | 10.1021/jm990196h |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70032313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70032313</sourcerecordid><originalsourceid>FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</originalsourceid><addsrcrecordid>eNptkM-O0zAQhy0EYsvCgRdAPgBiDyn-F6c5dqNlQRS20gZxtFx3TF0Su9gJojwEz0xCqoUDpxnNfPpp5kPoKSVzShh9vW_LktBS7u6hGc0ZycSCiPtoRghjGZOMn6FHKe0JIZwy_hCdUSKKkhM2Q78qHbcuJGjAdO474KXvnEtmB60zeFmvs1vwyf1ZrUOnU3J9i6ud9h4a_Or9EtfrC3xzAA8xzbGc4ytrhygcLP4Qts46ozsXfMK6w5Ucx5fgf4bDMWp_bHB11D586bV3W-chPUYPrG4SPDnVc_TpzVVdvc1WN9fvquUq00KILtO2KKUQzMB2UVhOpZV87DY5IRuS6wUprC01sZqAoMbmC5PLXIqcGCuBUn6OXk65hxi-9ZA61Q5PQ9NoD6FPqhhUMU75AF5MoIkhpQhWHaJrdTwqStQoX93JH9hnp9B-08L2H3KyPQDPT4BORjd2UGBc-suVBcvZeFw2YS518ONureNXJQte5Kpe36qPoi5Wn68v1Rj7YuK1SWof-ugHdf-57zePq6cx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70032313</pqid></control><display><type>article</type><title>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Ding, Charles Z ; Rovnyak, George C ; Misra, Raj N ; Grover, Gary J ; Miller, Arthur V ; Ahmed, Syed Z ; Kelly, Yolanda ; Normandin, Diane E ; Sleph, Paul G ; Atwal, Karnail S</creator><creatorcontrib>Ding, Charles Z ; Rovnyak, George C ; Misra, Raj N ; Grover, Gary J ; Miller, Arthur V ; Ahmed, Syed Z ; Kelly, Yolanda ; Normandin, Diane E ; Sleph, Paul G ; Atwal, Karnail S</creatorcontrib><description>The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm990196h</identifier><identifier>PMID: 10479302</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Benzopyrans - chemical synthesis ; Benzopyrans - chemistry ; Benzopyrans - pharmacology ; Biological and medical sciences ; Cardiotonic Agents - chemistry ; Cardiotonic Agents - pharmacology ; Cardiovascular system ; Glyburide - pharmacology ; Guanidines - chemical synthesis ; Guanidines - chemistry ; Guanidines - pharmacology ; Heart - drug effects ; Medical sciences ; Miscellaneous ; Muscle Contraction - drug effects ; Myocardial Ischemia - drug therapy ; Pharmacology. Drug treatments ; Potassium Channels - agonists ; Rats ; Vasodilation - drug effects ; Vasodilator Agents - chemistry ; Vasodilator Agents - pharmacology</subject><ispartof>Journal of medicinal chemistry, 1999-09, Vol.42 (18), p.3711-3717</ispartof><rights>Copyright © 1999 American Chemical Society</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</citedby><cites>FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm990196h$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm990196h$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1972521$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10479302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ding, Charles Z</creatorcontrib><creatorcontrib>Rovnyak, George C</creatorcontrib><creatorcontrib>Misra, Raj N</creatorcontrib><creatorcontrib>Grover, Gary J</creatorcontrib><creatorcontrib>Miller, Arthur V</creatorcontrib><creatorcontrib>Ahmed, Syed Z</creatorcontrib><creatorcontrib>Kelly, Yolanda</creatorcontrib><creatorcontrib>Normandin, Diane E</creatorcontrib><creatorcontrib>Sleph, Paul G</creatorcontrib><creatorcontrib>Atwal, Karnail S</creatorcontrib><title>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.</description><subject>Animals</subject><subject>Benzopyrans - chemical synthesis</subject><subject>Benzopyrans - chemistry</subject><subject>Benzopyrans - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiotonic Agents - chemistry</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Cardiovascular system</subject><subject>Glyburide - pharmacology</subject><subject>Guanidines - chemical synthesis</subject><subject>Guanidines - chemistry</subject><subject>Guanidines - pharmacology</subject><subject>Heart - drug effects</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Muscle Contraction - drug effects</subject><subject>Myocardial Ischemia - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium Channels - agonists</subject><subject>Rats</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - chemistry</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkM-O0zAQhy0EYsvCgRdAPgBiDyn-F6c5dqNlQRS20gZxtFx3TF0Su9gJojwEz0xCqoUDpxnNfPpp5kPoKSVzShh9vW_LktBS7u6hGc0ZycSCiPtoRghjGZOMn6FHKe0JIZwy_hCdUSKKkhM2Q78qHbcuJGjAdO474KXvnEtmB60zeFmvs1vwyf1ZrUOnU3J9i6ud9h4a_Or9EtfrC3xzAA8xzbGc4ytrhygcLP4Qts46ozsXfMK6w5Ucx5fgf4bDMWp_bHB11D586bV3W-chPUYPrG4SPDnVc_TpzVVdvc1WN9fvquUq00KILtO2KKUQzMB2UVhOpZV87DY5IRuS6wUprC01sZqAoMbmC5PLXIqcGCuBUn6OXk65hxi-9ZA61Q5PQ9NoD6FPqhhUMU75AF5MoIkhpQhWHaJrdTwqStQoX93JH9hnp9B-08L2H3KyPQDPT4BORjd2UGBc-suVBcvZeFw2YS518ONureNXJQte5Kpe36qPoi5Wn68v1Rj7YuK1SWof-ugHdf-57zePq6cx</recordid><startdate>19990909</startdate><enddate>19990909</enddate><creator>Ding, Charles Z</creator><creator>Rovnyak, George C</creator><creator>Misra, Raj N</creator><creator>Grover, Gary J</creator><creator>Miller, Arthur V</creator><creator>Ahmed, Syed Z</creator><creator>Kelly, Yolanda</creator><creator>Normandin, Diane E</creator><creator>Sleph, Paul G</creator><creator>Atwal, Karnail S</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990909</creationdate><title>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</title><author>Ding, Charles Z ; Rovnyak, George C ; Misra, Raj N ; Grover, Gary J ; Miller, Arthur V ; Ahmed, Syed Z ; Kelly, Yolanda ; Normandin, Diane E ; Sleph, Paul G ; Atwal, Karnail S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Benzopyrans - chemical synthesis</topic><topic>Benzopyrans - chemistry</topic><topic>Benzopyrans - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiotonic Agents - chemistry</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Cardiovascular system</topic><topic>Glyburide - pharmacology</topic><topic>Guanidines - chemical synthesis</topic><topic>Guanidines - chemistry</topic><topic>Guanidines - pharmacology</topic><topic>Heart - drug effects</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Muscle Contraction - drug effects</topic><topic>Myocardial Ischemia - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium Channels - agonists</topic><topic>Rats</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - chemistry</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ding, Charles Z</creatorcontrib><creatorcontrib>Rovnyak, George C</creatorcontrib><creatorcontrib>Misra, Raj N</creatorcontrib><creatorcontrib>Grover, Gary J</creatorcontrib><creatorcontrib>Miller, Arthur V</creatorcontrib><creatorcontrib>Ahmed, Syed Z</creatorcontrib><creatorcontrib>Kelly, Yolanda</creatorcontrib><creatorcontrib>Normandin, Diane E</creatorcontrib><creatorcontrib>Sleph, Paul G</creatorcontrib><creatorcontrib>Atwal, Karnail S</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ding, Charles Z</au><au>Rovnyak, George C</au><au>Misra, Raj N</au><au>Grover, Gary J</au><au>Miller, Arthur V</au><au>Ahmed, Syed Z</au><au>Kelly, Yolanda</au><au>Normandin, Diane E</au><au>Sleph, Paul G</au><au>Atwal, Karnail S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1999-09-09</date><risdate>1999</risdate><volume>42</volume><issue>18</issue><spage>3711</spage><epage>3717</epage><pages>3711-3717</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>10479302</pmid><doi>10.1021/jm990196h</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1999-09, Vol.42 (18), p.3711-3717 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_70032313 |
source | MEDLINE; American Chemical Society Journals |
subjects | Animals Benzopyrans - chemical synthesis Benzopyrans - chemistry Benzopyrans - pharmacology Biological and medical sciences Cardiotonic Agents - chemistry Cardiotonic Agents - pharmacology Cardiovascular system Glyburide - pharmacology Guanidines - chemical synthesis Guanidines - chemistry Guanidines - pharmacology Heart - drug effects Medical sciences Miscellaneous Muscle Contraction - drug effects Myocardial Ischemia - drug therapy Pharmacology. Drug treatments Potassium Channels - agonists Rats Vasodilation - drug effects Vasodilator Agents - chemistry Vasodilator Agents - pharmacology |
title | Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A06%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardioselective%20Antiischemic%20ATP-Sensitive%20Potassium%20Channel%20(KA%20TP)%20Openers.%206.%20Effect%20of%20Modifications%20at%20C6%20of%20Benzopyranyl%20Cyanoguanidines&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Ding,%20Charles%20Z&rft.date=1999-09-09&rft.volume=42&rft.issue=18&rft.spage=3711&rft.epage=3717&rft.pages=3711-3717&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm990196h&rft_dat=%3Cproquest_cross%3E70032313%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70032313&rft_id=info:pmid/10479302&rfr_iscdi=true |